Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics Q1 2025 Earnings Report

Artiva Biotherapeutics logo
$1.99 +0.02 (+0.93%)
As of 12:26 PM Eastern

Artiva Biotherapeutics EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Artiva Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artiva Biotherapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Artiva Biotherapeutics' Q2 2025 earnings is scheduled for Monday, June 23, 2025

Artiva Biotherapeutics Earnings Headlines

Recession Fears Mounting? 2 AI Stocks to Watch Now
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
See More Artiva Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email.

About Artiva Biotherapeutics

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

View Artiva Biotherapeutics Profile

More Earnings Resources from MarketBeat